BIOMEA FUSION, INC. RECRUITING STUDIES:

• COVALENT-112 – Type 1 Diabetes:

COVALENT-112 is a Phase 2 trial designed to examine beta-cell function, insulin sensitivity, and both glucose and lipid metabolism in participants with T1D treated with BMF-219. The study will last around 1 year.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

ELI LILLY AND CO. RECRUITING STUDIES:

• J2A-MC- GZGS – T2DM/Overweight/Obesity

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• J1I-MC-GZBU – T2DM/Kidney Disease/Overweight and Obesity

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• J2A-MC-GZGT- T2DM/Overweight And Obesity

The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

NOVO NORDISK RECRUITING STUDIES:

• NN9388-4896 (REIMAGINE 2) – T2DM/Overweight and Obesity

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. Duration of the Trial is around 1.5 years.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• NN9388-4894 (REIMAGINE 4) –Overweight and Obesity/T2DM

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight and their blood sugar. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. Duration of the Trial is around 1.5 years.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

REATA PHARMACEUTICALS RECRUITING STUDIES:

• 901-C-2102 (CYPRESS Trial) – Diabetic Neuropathy

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and PK of RTA 901 in qualified subjects with Diabetic peripheral neuropathic pain. The duration of each part of the study will be approximately 20 weeks.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

ELI LILLY AND CO. NON-RECRUITING STUDIES:

• I8H-MC-BDCW – T2DM

NOVO NORDISK NON-RECRUITING STUDIES:

• NN9536-7545 (STEP-UP)- T2DM/Overweight/Obesity

• NN9838-4609 (REDEFINE 2) – T2DM/ Overweight/Obesity

• NN1535-4591 (COMBINE 1) – T2DM

COMPLETED STUDIES:

  • Afimmune – DS102A-07-CV1 – T2DM/ Hypertriglyceridemia – 2022

  • Andromeda Biotech Ltd. – DiaPep277-1001 – T1DM – 2014

  • Anji Pharma – ANJ900D3501 – T2DM – 2023

  • AstraZeneca – D9183C0001 – DKD – 2023

  • Bayer – 17530 (FIGARO) – DKD – 2021

  • Boehringer Ingelheim – 1218.89 (MARLINA) – T2DM – 2016

  • Boehringer Ingelheim – 1218.22 (CARMELINA) – T2DM – 2018

  • CSL Behring – CSL346_2001 (MANEUVER) – DKD – 2022

  • Eli Lilly and Co. – H9X-MC-GBDX – T2DM / CKD – 2016

  • Eli Lilly and Co. – I8B-MC-ITSW – T2DM – 2022

  • Eli Lilly and Co. – J1I-MC-GZBD – T2DM – 2022

  • Eli Lilly and Co. – I8F-MC-GPHL (SURMOUNT 2) – T2DM/ Overweight/Obesity – 2023

  • GlaxoSmithKline – GSK-200952 – T2DM -2017

  • Ironwood Pharmaceuticals – C1973-203 – T2DM w/ Diabetic Nephropathy – 2019

  • Janssen Research & Development, LLC – 28431754DIA2004 – T1DM – 2015

  • Janssen Research & Development, LLC – 28431754DNE3001 (CREDENCE) – T2DM/Diabetic Nephropathy – 2018

  • Lexicon Pharmaceuticals – LX4211.1.309 – T1DM – 2014

  • Lexicon Pharmaceuticals – EFC14834 – T2DM – 2019

  • Lexicon Pharmaceuticals – EFC14868 (SOTA-INS) – T2DM – 2019

  • Merck Sharp & Dohme LLC – MK-0431D-266 – T2DM -2013

  • Merck Sharp & Dohme LLC – MK-3102_027 – T2DM – 2014

  • Merck Sharp & Dohme LLC – MK-3102-016 – T2DM – 2015

  • Merck Sharp & Dohme LLC – MK-3102-019 -T2DM – 2016

  • Merck Sharp & Dohme LLC – MK-3102-018 – T2DM – 2017

  • Merck Sharp & Dohme LLC – MK-8835-004 B1521021 – T2Dm – 2020

  • Mylan Inc. – MYL-1501D-3004 – T1DM – 2019

  • Mylan Inc. – MYL-1601D-3001 (GAZELLE) – T1DM – 2020

  • Novo Nordisk – EX9536-4388 (select) – Overweight/Obesity – 2023

  • Novo Nordisk – NN1218-3852 – T1DM – 2015

  • Novo Nordisk – NN2211-4059 (LIRA SWITCH) – T2DM – 2015

  • Novo Nordisk – NN1250-3995 (SWITCH 1) – T1DM – 2016

  • Novo Nordisk – NN9828-4150 – T1DM – 2019

  • Novo Nordisk – NN1535-4593 (COMBINE 3) – T2DM

  • Novo Nordisk – NN1436-4478 (ONWARDS 2) – T2DM – 2022

  • Novo Nordisk – NN1436-4625 (ONWARDS 6) – T1DM – 2022

  • Novo Nordisk – NN9838-4862 – T2DM – 2022

  • Sanofi – DRI13940 – T2DM – 2017

  • Sanofi – LPS14347 – T2DM – 2018

  • Sanofi – EFC15081 (GEMELLI 1) – T1DM/T2DM – 2019

  • Sanofi – EFC15178 (GEMELLI X) – T1DM – 2020

  • Teijin America Inc. – TMX-049DN-201 – DKD – 2019

info@PlanItResearch.com